Research Program C: Cancer Risk Factors and Prevention


Below you will find DKFZ divisions and research groups of the Research Program Cancer Risk Factors and Prevention who are interested in recruiting Postdocs within the 2018 DKFZ Postdoctoral Fellowships Selection.

Please note that this is not an exhaustive list and new groups are continously added.

You may also contact the principal investigator of the DKFZ research group of your choice directly to discuss about current possibilities. More information about hiring labs can be found below and descriptions of DKFZ research programs via the general topic locator.

< BACK to overview page

Epigenomics and Cancer Risk Factors – Prof. Dr. Christoph Plass


Epigenetic mechanisms, including DNA and histone modifications, remodeling of the chromatin and non-coding RNAs, are important regulators of natural processes from early development to aging. The Division “Epigenomics and Cancer Risk Factors” is specifically interested in epigenetic alterations leading to various types of cancer, but also to other diseases such as radiation-induced fibrosis, chronic pulmonary obstruction and the metabolic syndrome.
Using diverse wet lab and computational technologies, our specific aims are to

•    investigate how genomic and epigenomic mechanisms interact in the deregulation of cancer genes,
•    infer the tumor cell of origin from DNA methylomes,
•    explore epigenetic tumor heterogeneity,
•    understand epigenetic gene regulation during early differentiation processes,
•    discover epigenetic modifications as modulators of disease risk,
•    understand the role of epigenetic mechanisms in immunology,
•    identify and validate DNA methylation-based biomarkers,
•    characterize epigenetic alterations in rodent models of cancer development to identify early and potentially initiating epigenetic events
•    investigate the influence of dietary factors on epigenetic regulation of gene expression and
•    develop novel strategies for epigenetic therapies and prevention.


We offer several projects dealing with epigenetic research questions and related to several tumor types from leukemia, breast, prostate, lung, bile duct and pancreatic cancer to giant cell tumors of the bone. Most projects range from integrated NGS-based genome-wide genetic, epigenetic and transcriptomic analyses to experimental validation in cancer samples and in in vitro models using up to date technologies such as CRISPR/Cas9-based technologies for epigenetic editing.

Please visit our website for further information on our research and recent publications.


to top